
Anti-Human/Mouse/Rat Phospho-AKT1/3 (Tyr437/434) Polyclonal Antibody**Polyclonal Antibody****Cat.NO.: PA01827**

3th Edition

Description:AKT1 and AKT3 are members of the AKT, also called PKB, serine/threonine protein kinase family. AKT kinases are known to be regulators of cell signaling in response to insulin and growth factors. They are involved in a wide variety of biological processes including cell proliferation, differentiation, apoptosis, tumorigenesis, as well as glycogen synthesis and glucose uptake. This kinase has been shown to be stimulated by platelet derived growth factor (PDGF), insulin, and insulin like growth factor 1 (IGF1). Alternatively splice transcript variants encoding distinct isoforms have been described. The protein kinase encoded by the AKT1 gene is catalytically inactive in serum starved primary and immortalized fibroblasts. AKT1 and the related AKT2 are activated by platelet derived growth factor. The activation is rapid and specific, and it is abrogated by mutations in the pleckstrin homology domain of AKT1. It was shown that the activation occurs through phosphatidylinositol 3 kinase. In the developing nervous system AKT is a critical mediator of growth factor induced neuronal survival. Survival factors can suppress apoptosis in a transcription-independent manner by activating the serine/threonine kinase AKT1, which then phosphorylates and inactivates components of the apoptotic machinery. Multiple alternatively spliced transcript variants have been found for this gene.

Antigen:Synthesized peptide derived from human Akt1/3 around the phosphorylation site of Tyr437/434

Form:

How to use:1.0 ml distilled water will be added to the product

Stability: Lyophilized product, 5 years at 2 – 8°C; Solution, 2 years at –20°C

Dilution:PBS (pH7.4) containing 1% BSA

Application:This antibody can be used for western blotting in concentration of 1?5?g/ml.

Specificity:AKT1 is Expressed in prostate cancer and levels increase from the normal to the malignant state (at protein level). Expressed in all human cell types so far analyzed. The Tyr-176 phosphorylated form shows a significant increase in expression in breast cancers during the progressive stages i.e. normal to hyperplasia (ADH), ductal carcinoma in situ (DCIS), invasive ductal carcinoma (IDC) and lymph node metastatic (LNMM) stages.